Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00607594
Other study ID # NCI-2009-00188
Secondary ID PHL-052CDR000058
Status Completed
Phase Phase 2
First received
Last updated
Start date January 2008
Est. completion date April 2012

Study information

Verified date July 2018
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial is studying how well saracatinib works in treating patients with locally advanced or metastatic stomach or gastroesophageal junction cancer. Saracatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


Description:

PRIMARY OBJECTIVES:

I. To assess the objective disease control rate (i.e., partial or complete response as defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria or stable disease for ≥ 16 weeks) in patients with locally advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction treated with AZD0530 (saracatinib).

SECONDARY OBJECTIVES:

I. To assess the median time to disease progression, median overall survival, and 1-year survival rate in these patients.

II. To assess the toxicity of AZD0530 in these patients. III. To evaluate potential predictive markers by assessing pretreatment intratumoral levels of src, Y419 phospho-src (P-Src), and c-terminal src kinase (Csk) in archival tumor biopsies.

OUTLINE:

Patients receive saracatinib orally (PO) once daily (QD) in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at least every 2 months.


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date April 2012
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEJ)

- Tumors of the GEJ must be sub-specified as type I, II, or III using the Siewert classification

- Metastatic or locally advanced disease

- Patients with local/regional disease only, must have unresectable disease

- Measurable disease, defined as = 1 lesion that can be accurately measured in = 1 dimension (longest diameter to be recorded) as = 20 mm by conventional techniques or as = 10 mm by spiral computed tomography (CT) scan

- No known brain metastases

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2 OR Karnofsky PS 60-100%

- Life expectancy > 3 months

- Platelet count = 100,000/mm³

- Leukocytes = 3,000/mm³

- Absolute neutrophil count = 1,500/mm³

- Hemoglobin > 9 g/dL

- Total bilirubin normal

- Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) = 2.5 times upper limit of normal

- Creatinine normal OR creatinine clearance = 60 mL/min

- Urine protein creatinine ratio < 1.0 OR urine protein < 1,000 mg by 24-hour urine collection

Exclusion Criteria:

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No condition that potentially impairs the ability to swallow or absorb AZD0530, including any of the following:

- Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation

- Active peptic ulcer disease

- Short gut syndrome

- Malabsorption syndrome of any type

- Total or partial bowel obstruction

- Inability to tolerate oral medications

- No history of allergic reactions attributed to compounds of similar chemical or biologic composition to AZD0530

- No QTc prolongation (defined as a QTc interval = 460 msec) or other significant electrocardiogram (ECG) abnormalities

- No poorly controlled hypertension (i.e., systolic blood pressure [BP] = 140 mm Hg or diastolic BP = 90 mm Hg)

- No history of ischemic heart disease, including myocardial infarction

- No concurrent cardiac dysfunction including, but not limited to, any of the following:

- Symptomatic congestive heart failure

- Unstable angina pectoris

- Cardiac arrhythmia

- No other concurrent uncontrolled illness, including ongoing or active infection or psychiatric illness/social situations, that would limit compliance with study requirements

- Prior chemotherapy allowed provided it was administered as part of initial curative intent therapy (i.e., neoadjuvant therapy, adjuvant therapy and/or concurrently with radiotherapy) in combination with surgery

- At least 4 weeks since prior chemotherapy

- At least 4 weeks since prior and no more than 1 line of palliative chemotherapy for advanced disease

- At least 4 weeks since prior radiotherapy and recovered

- At least 4 weeks since prior major surgery and recovered

- No cytochrome 450 3A4 (CYP3A4) active agents or substances for = 7 days before, during, and for = 7 days after completion of study treatment

- No other concurrent investigational agents

- No other concurrent anticancer therapy

- No concurrent combination antiretroviral therapy for human immunodeficiency virus (HIV)-positive patients

Study Design


Intervention

Drug:
saracatinib
Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.

Locations

Country Name City State
Canada Cross Cancer Institute Edmonton Alberta
Canada Juravinski Cancer Centre at Hamilton Health Sciences Hamilton Ontario
Canada McGill University Department of Oncology Montreal Quebec
Canada University Health Network-Princess Margaret Hospital Toronto Ontario
United States Hamilton Medical Center Dalton Georgia

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Countries where clinical trial is conducted

United States,  Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Objective Tumor Response (Defined as Partial [PR] or Complete Response [CR] by RECIST Criteria) PR is defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD. CR is defined as disappearance of all non-target lesions and normalization of tumor marker level. Every 2 weeks for the first 4 weeks, and then every 4-8 weeks thereafter, for at least 16 weeks up to 37 weeks
Primary Prolonged Stable Disease Rate (Defined as Stable Disease for = 16 Weeks) Every 2 weeks for the first 4 weeks, and then every 4-8 weeks thereafter, for at least 16 weeks up to 37 weeks
Secondary Time to Progression Progression is defined using Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) as a 20% increase in the sum of the longest diameter of target lesions,or a measurable increase in non-target lesions, or the appearance of new lesions. Up to 1 year (median, 6 month, 1-year)
Secondary Progression-free Survival Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. Measured from the date of enrollment to progression, death or last contact, or last tumor assessment before the start of further anti-tumor therapy
Secondary Median Survival Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. Up to 1 year
Secondary Overall Survival The Kaplan-Meier method will be used to estimate overall and time to progression estimates. Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. Up to 1 year (median, 6 months, and 1 year)
Secondary Highest Grade Toxicity as Assessed by the National Cancer Institute (NCI) Common Toxicity Criteria Version 3.0. Toxicities will be graded using the National Cancer Institute (NCI) Common Toxicity Criteria Version 3.0. Weekly during treatment
Secondary Patient Tolerability Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. Weekly during treatment
Secondary Association Between Correlative Markers and Clinical Outcomes Standard descriptive statistics, such as the mean, median, range and proportion, will be used to summarize the patient sample and to estimate parameters of interest. Ninety-five percent confidence intervals will be provided for estimates of interest where possible. At baseline, 6 months, and then at 1 year
See also
  Status Clinical Trial Phase
Terminated NCT02234180 - Regorafenib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery Phase 2
Terminated NCT01705340 - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Phase 1
Completed NCT01178944 - Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer Phase 2
Completed NCT00982592 - Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer Phase 2
Completed NCT00991952 - Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery Phase 2
Terminated NCT00732745 - Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction Phase 1
Completed NCT00253370 - Sorafenib, Docetaxel, and Cisplatin in Treating Patients With Metastatic or Advanced Gastric or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT04773769 - Study of Guanábana Leaves for The Treatment of Patients With Gastric, Gastroesophageal Junction, Pancreatic and Colorectal Adenocarcinomas; Hepatocellular Carcinoma, and Low Grade Lymphomas N/A
Completed NCT02918162 - Perioperative Chemo and Pembrolizumab in Gastric Cancer Phase 2
Completed NCT01612546 - Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery Phase 2
Active, not recruiting NCT01939275 - 64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer N/A
Completed NCT02013154 - A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab Phase 1
Completed NCT01107639 - Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery Phase 3
Completed NCT01855854 - Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH Phase 2
Withdrawn NCT02344810 - C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer Phase 1/Phase 2
Completed NCT01243398 - Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy Phase 3
Completed NCT00084617 - Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma Phase 2
Completed NCT01360086 - Fluorouracil, Cisplatin, Leucovorin Calcium, and Cetuximab in Treating Patients With Adenocarcinoma of the Stomach or Gastroesophageal Junction Phase 2
Terminated NCT00064259 - A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer Phase 1/Phase 2
Completed NCT00045526 - Erlotinib Hydrochloride in Treating Patients With Advanced Esophageal Cancer or Stomach Cancer Phase 2